Anocca

Biotech · Sodertalje, SE

Clinical-stage T-cell immunotherapy company developing TCR-T therapies for hard-to-treat cancers.

Founders

Reagan Jarvis (New Zealand · ♂) — A New Zealand-born biochemist who studied innate immune signaling, he pitched a new company idea to investor Mikael Blomqvist and co-founded Anocca in Sweden in 2014 as scientific founder and CEO to engineer TCR-T cell therapies for hard-to-treat cancers.
Mikael Blomqvist (Sweden · ♂) — A Swedish entrepreneur and investor who asked Jarvis to pitch ideas, he co-founded Anocca and backed it via his Michano AB firm with early seed funding in 2014.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Aug 2025	Funding round Anocca raised $46 million led by Mellby Gard to bring VIDAR-1 into the clinic, a TCR-T therapy targeting mutant KRAS in pancreatic cancer.	$46M
Dec 2022	Debt Sweden-based cell therapy biotech Anocca raised EUR25M in venture debt from the European Investment Bank under InvestEU to advance its T-cell immunotherapies.	$27M
Aug 2021	Series B Swedish biotech Anocca raised a USD 47M Series B from Swedbank Robur Ny Teknik, Ramsbury Invest and others to advance its T-cell therapies.	$47M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.